All In Biotech

Drug Trial Radar · NCT01613248

A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006)

A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine

Last checked: Nov 19, 2026Latest source record: Jan 8, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 834 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

834

Actual

Start

Jul 1, 2012

Primary completion

Dec 1, 2012

Study completion Dec 1, 2012

Sponsor

Lead sponsor
AllerganAbbVie (ABBV)
Sponsor type
Industry
First posted
Jun 7, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the effectiveness, safety and tolerability of a range of doses of MK-1602 versus placebo in the treatment of acute migraine.

Conditions

  • Migraine

Interventions

  • MK-1602Drug

    Single 1, 10, 25, 50 or 100 mg dose of MK-1602 taken at onset of migraine of moderate or severe intensity. Dosage form is film coated tablet for oral administration. Dose is provided to participants as a blinded bottle of tablets packaged to achieve the various MK-1602 dose levels to be studied. Participants will be instructed to take all study medication from the bottle when they treat their migraine headache.

  • Placebo-matching MK-1602Drug

    Single administration of placebo-matching MK-1602 taken at onset of migraine of moderate or severe intensity. Dosage form is film coated tablet for oral administration. Dose is provided to participants as a blinded bottle of tablets packaged to achieve placebo study medication. Participants will be instructed to take all study medication from the bottle when they treat their migraine headache.

  • Rescue medicationDrug

    If moderate or severe migraine headache pain continues 2 hours after dose of study medication or if migraine headache comes back within 48 hours, Participants will be allowed to take their own rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs \[NSAIDs\]), anti-emetics, triptans or other medication not explicitly excluded.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Reporting Pain Freedom (PF) at 2 Hours Post-DoseTime frame: 2 hours post-dose
  2. Percentage of Participants Reporting Pain Relief (PR) at 2 Hours Post-DoseTime frame: 2 hours post-dose
  3. Number of Participants With One or More Adverse Events Within 48 Hours Post-DoseTime frame: Up to 48 hours post-dose
  4. Number of Participants With One or More Adverse Events Within 14 Days Post-DoseTime frame: Up to 14 days post-dose
  5. Number of Participants Who Discontinued From Study Due to Adverse EventsTime frame: Up to 5 weeks post-dose

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.